Report #2846528

Overview

Sex

Female

Age

Age unknown

State

MO

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

intramuscular versus subcutaneous administration of PRIORIX.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) (batch number 7975C, expiry date 01-MAR-2027) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular use). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: intramuscular versus subcutaneous administration of PRIORIX.). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 11-JUN-2025 Bachelor of Science in Nursing called to ask, are there any safety concerns regarding the intramuscular versus subcutaneous administration of Priorix which led to incorrect route of product administration. Vaccine details and patient demographics were obtained in this call. No vaccination was confirmed from the Bachelor of Science in Nursing's end. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.